Sipuleucel-T
Sipuleucel-T is a pharmaceutical drug with 32 clinical trials. Currently 4 active trials ongoing. Historical success rate of 92.0%.
Success Metrics
Based on 23 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
18
Mid Stage
5
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
85.2%
23 of 27 finished
14.8%
4 ended early
4
trials recruiting
32
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer
Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
Clinical Trials (32)
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer
Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer
Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
PROvenge Treatment and Early Cancer Treatment
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 32